Forsta AP Fonden Sells 200 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Forsta AP Fonden cut its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 97,200 shares of the medical equipment provider’s stock after selling 200 shares during the period. Forsta AP Fonden’s holdings in Zimmer Biomet were worth $10,267,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Dunhill Financial LLC raised its stake in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet in the third quarter valued at about $28,000. Bangor Savings Bank acquired a new position in Zimmer Biomet in the third quarter worth about $31,000. Brooklyn Investment Group bought a new position in Zimmer Biomet during the third quarter worth about $35,000. Finally, Quarry LP acquired a new stake in Zimmer Biomet during the second quarter valued at approximately $53,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

ZBH stock opened at $110.63 on Friday. Zimmer Biomet Holdings, Inc. has a twelve month low of $100.67 and a twelve month high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The company has a market cap of $22.02 billion, a P/E ratio of 21.03, a price-to-earnings-growth ratio of 1.88 and a beta of 1.02. The business’s fifty day moving average is $107.91 and its 200-day moving average is $108.22.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company’s revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the business earned $1.65 earnings per share. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date is Monday, December 30th. Zimmer Biomet’s payout ratio is 18.25%.

Wall Street Analyst Weigh In

ZBH has been the topic of several recent analyst reports. Raymond James decreased their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Wednesday. BTIG Research cut their price target on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd. Stifel Nicolaus upped their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada lifted their target price on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, November 4th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $124.11.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.